Do analysts recommend JF or ENTO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score J And Friends 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, JF or ENTO?

J And Friends has higher revenue and earnings than Entero Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio J And Friends $1.60M 10.90 -$1.32M N/A N/A Entero Therapeutics N/A N/A -$18.06M -$1.69 N/A

Is JF or ENTO more profitable?

J And Friends' return on equity of 0.00% beat Entero Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets J And Friends N/A N/A N/A Entero Therapeutics N/A -461.02% -14.72%

Do analysts prefer ENTO or HPAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Helport AI 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, ENTO or HPAI?

Helport AI has higher revenue and earnings than Entero Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Entero Therapeutics N/A N/A -$18.06M -$1.69 N/A Helport AI $34.86M 0.52 $1.86M N/A N/A

Is ENTO or HPAI more profitable?

Helport AI's return on equity of 0.00% beat Entero Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Entero Therapeutics N/A -461.02% -14.72% Helport AI N/A N/A N/A

Do analysts rate ENTO or AIXC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, ENTO or AIXC?

Entero Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Entero Therapeutics N/A N/A -$18.06M -$1.69 N/A Qualigen Therapeutics N/A N/A -$16.97M -$5.68 N/A

Is ENTO or AIXC more profitable?

Entero Therapeutics' return on equity of -461.02% beat Qualigen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Entero Therapeutics N/A -461.02% -14.72% Qualigen Therapeutics N/A -599.14% -86.38%

Do analysts recommend CYN or ENTO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyngn Inc. Common Stock 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer APCX or ENTO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AppTech Payments 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Entero Therapeutics (ENTO) Competitors

$3.79 +0.50 (+15.20%)

As of 08/13/2026

Compare

ENTO vs. JF, HPAI, AIXC, CYN, and APCX

Should you buy Entero Therapeutics stock or one of its competitors? Entero Therapeutics's main competitors and comparable companies include J And Friends (JF), Helport AI (HPAI), Qualigen Therapeutics (AIXC), Cyngn Inc. Common Stock (CYN), and AppTech Payments (APCX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Entero Therapeutics compare to J And Friends?

J And Friends (NASDAQ:JF) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap technology companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

J And Friends' return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
J And Friends	N/A	N/A	N/A
Entero Therapeutics	N/A	-461.02%	-14.72%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
J And Friends	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

6.6% of J And Friends shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 4.1% of J And Friends shares are held by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, J And Friends had 1 more articles in the media than Entero Therapeutics. MarketBeat recorded 1 mentions for J And Friends and 0 mentions for Entero Therapeutics. J And Friends' average media sentiment score of 1.91 beat Entero Therapeutics' score of 0.00 indicating that J And Friends is being referred to more favorably in the media.

Company	Overall Sentiment
J And Friends	Very Positive
Entero Therapeutics	Neutral

J And Friends has higher revenue and earnings than Entero Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
J And Friends	$1.60M	10.90	-$1.32M	N/A	N/A
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A

J And Friends has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

Summary

J And Friends beats Entero Therapeutics on 7 of the 9 factors compared between the two stocks.

How does Entero Therapeutics compare to Helport AI?

Entero Therapeutics (NASDAQ:ENTO) and Helport AI (NASDAQ:HPAI) are both small-cap technology companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

In the previous week, Helport AI had 2 more articles in the media than Entero Therapeutics. MarketBeat recorded 2 mentions for Helport AI and 0 mentions for Entero Therapeutics. Helport AI's average media sentiment score of 0.44 beat Entero Therapeutics' score of 0.00 indicating that Helport AI is being referred to more favorably in the news media.

Company	Overall Sentiment
Entero Therapeutics	Neutral
Helport AI	Neutral

Entero Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, Helport AI has a beta of -0.04, indicating that its share price is 104% less volatile than the broader market.

Helport AI has higher revenue and earnings than Entero Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A
Helport AI	$34.86M	0.52	$1.86M	N/A	N/A

12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 62.4% of Helport AI shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by company insiders. Comparatively, 13.3% of Helport AI shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Helport AI's return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-461.02%	-14.72%
Helport AI	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Helport AI	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Helport AI beats Entero Therapeutics on 8 of the 9 factors compared between the two stocks.

How does Entero Therapeutics compare to Qualigen Therapeutics?

Entero Therapeutics (NASDAQ:ENTO) and Qualigen Therapeutics (NASDAQ:AIXC) are both small-cap technology companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Entero Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

Entero Therapeutics' return on equity of -461.02% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-461.02%	-14.72%
Qualigen Therapeutics	N/A	-599.14%	-86.38%

In the previous week, Qualigen Therapeutics had 3 more articles in the media than Entero Therapeutics. MarketBeat recorded 3 mentions for Qualigen Therapeutics and 0 mentions for Entero Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.66 beat Entero Therapeutics' score of 0.00 indicating that Qualigen Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Entero Therapeutics	Neutral
Qualigen Therapeutics	Positive

12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by insiders. Comparatively, 1.2% of Qualigen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Entero Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$5.68	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Entero Therapeutics and Qualigen Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Entero Therapeutics compare to Cyngn Inc. Common Stock?

Cyngn Inc. Common Stock (NASDAQ:CYN) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

73.2% of Cyngn Inc. Common Stock shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 0.0% of Cyngn Inc. Common Stock shares are held by insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Cyngn Inc. Common Stock had 2 more articles in the media than Entero Therapeutics. MarketBeat recorded 2 mentions for Cyngn Inc. Common Stock and 0 mentions for Entero Therapeutics. Cyngn Inc. Common Stock's average media sentiment score of 0.46 beat Entero Therapeutics' score of 0.00 indicating that Cyngn Inc. Common Stock is being referred to more favorably in the media.

Company	Overall Sentiment
Cyngn Inc. Common Stock	Neutral
Entero Therapeutics	Neutral

Entero Therapeutics has lower revenue, but higher earnings than Cyngn Inc. Common Stock. Entero Therapeutics is trading at a lower price-to-earnings ratio than Cyngn Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyngn Inc. Common Stock	$220K	72.76	-$23.47M	-$5.27	N/A
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A

Cyngn Inc. Common Stock has a beta of 0.06, indicating that its stock price is 94% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

Entero Therapeutics has a net margin of 0.00% compared to Cyngn Inc. Common Stock's net margin of -6,953.61%. Cyngn Inc. Common Stock's return on equity of -63.23% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyngn Inc. Common Stock	-6,953.61%	-63.23%	-50.50%
Entero Therapeutics	N/A	-461.02%	-14.72%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyngn Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cyngn Inc. Common Stock beats Entero Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Entero Therapeutics compare to AppTech Payments?

AppTech Payments (NASDAQ:APCX) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap technology companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

In the previous week, AppTech Payments' average media sentiment score of 0.00 equaled Entero Therapeutics'average media sentiment score.

Company	Overall Sentiment
AppTech Payments	Neutral
Entero Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AppTech Payments	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

5.2% of AppTech Payments shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 44.5% of AppTech Payments shares are held by insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Entero Therapeutics has lower revenue, but higher earnings than AppTech Payments. Entero Therapeutics is trading at a lower price-to-earnings ratio than AppTech Payments, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AppTech Payments	$276K	59.35	-$18.51M	-$0.23	N/A
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A

AppTech Payments has a beta of -0.44, indicating that its stock price is 144% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

Entero Therapeutics has a net margin of 0.00% compared to AppTech Payments' net margin of -3,119.45%. AppTech Payments' return on equity of -398.98% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AppTech Payments	-3,119.45%	-398.98%	-153.45%
Entero Therapeutics	N/A	-461.02%	-14.72%

Summary

Entero Therapeutics beats AppTech Payments on 6 of the 11 factors compared between the two stocks.

Get Entero Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENTO vs. The Competition

Export

Metric	Entero Therapeutics	Software Industry	Technology Sector	NASDAQ Exchange
Market Cap	$6.02M	$15.99B	$30.69B	$13.10B
Dividend Yield	N/A	3.43%	2.73%	10.45%
P/E Ratio	-2.24	127.92	75.53	25.28
Price / Sales	N/A	1,304.97	602.17	91.83
Price / Cash	N/A	48.98	53.72	50.90
Price / Book	-1.55	7.34	9.57	6.24
Net Income	-$18.06M	$436.26M	$681.19M	$347.60M
7 Day Performance	38.32%	0.15%	1.42%	1.06%
1 Month Performance	-1.30%	2.62%	2.75%	0.81%
1 Year Performance	107.10%	7.15%	199.68%	20.90%

Entero Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENTO Entero Therapeutics	N/A	$3.79 +15.2%	N/A	+106.0%	$6.02M	N/A	N/A	9
JF J And Friends	0.5152 of 5 stars	$0.95 +4.5%	N/A	N/A	$17.44M	$1.60M	N/A	78
HPAI Helport AI	0.4079 of 5 stars	$0.46 -2.0%	N/A	-87.9%	$17.11M	$34.86M	N/A	N/A	Short Interest Increase
AIXC Qualigen Therapeutics	0.5921 of 5 stars	$0.82 -0.6%	N/A	N/A	$16.62M	N/A	N/A	50	Earnings Report Short Interest Decrease Gap Down
CYN Cyngn Inc. Common Stock	0.607 of 5 stars	$1.12 +0.9%	N/A	N/A	$16.15M	$220K	N/A	62	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENTO) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entero Therapeutics (ENTO) Competitors

ENTO vs. JF, HPAI, AIXC, CYN, and APCX

How does Entero Therapeutics compare to J And Friends?

Summary

How does Entero Therapeutics compare to Helport AI?

Summary

How does Entero Therapeutics compare to Qualigen Therapeutics?

Summary

How does Entero Therapeutics compare to Cyngn Inc. Common Stock?

Summary

How does Entero Therapeutics compare to AppTech Payments?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTO vs. The Competition

Entero Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entero Therapeutics (ENTO) Competitors

ENTO vs. JF, HPAI, AIXC, CYN, and APCX

How does Entero Therapeutics compare to J And Friends?

Is JF or ENTO more profitable?

Do analysts recommend JF or ENTO?

Do insiders & institutionals believe in JF or ENTO?

Does the media favor JF or ENTO?

Which has better earnings and valuation, JF or ENTO?

Which has more risk & volatility, JF or ENTO?

Summary

How does Entero Therapeutics compare to Helport AI?

Does the media refer more to ENTO or HPAI?

Which has more risk & volatility, ENTO or HPAI?

Which has better valuation & earnings, ENTO or HPAI?

Do insiders & institutionals hold more shares of ENTO or HPAI?

Is ENTO or HPAI more profitable?

Do analysts prefer ENTO or HPAI?

Summary

How does Entero Therapeutics compare to Qualigen Therapeutics?

Which has more risk & volatility, ENTO or AIXC?

Is ENTO or AIXC more profitable?

Does the media prefer ENTO or AIXC?

Do institutionals and insiders hold more shares of ENTO or AIXC?

Which has stronger earnings and valuation, ENTO or AIXC?

Do analysts rate ENTO or AIXC?

Summary

How does Entero Therapeutics compare to Cyngn Inc. Common Stock?

Do institutionals & insiders have more ownership in CYN or ENTO?

Does the media prefer CYN or ENTO?

Which has higher valuation and earnings, CYN or ENTO?

Which has more volatility & risk, CYN or ENTO?

Is CYN or ENTO more profitable?

Do analysts recommend CYN or ENTO?

Summary

How does Entero Therapeutics compare to AppTech Payments?

Does the media prefer APCX or ENTO?

Do analysts prefer APCX or ENTO?

Do institutionals and insiders believe in APCX or ENTO?

Which has higher earnings and valuation, APCX or ENTO?

Which has more volatility & risk, APCX or ENTO?

Is APCX or ENTO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTO vs. The Competition

Entero Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools